PMID: 9449272Feb 4, 1998Paper

Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis

Antimicrobial Agents and Chemotherapy
J H RexE J Anaissie

Abstract

The trailing growth phenomenon seen when determining the susceptibilities of Candida isolates to the azole antifungal agents makes consistent endpoint determination difficult, and the M27-A method of the National Committee for Clinical Laboratory Standards addresses this problem by requiring an 80% reduction in growth after 48 h of incubation. For some isolates, however, minor variations of this endpoint criterion can produce up to 128-fold variations in the resulting MIC. To investigate the significance of this effect, isolates of Candida that exhibited various forms of trailing growth when tested against fluconazole were identified. The isolates were examined in a murine model of invasive candidiasis and were ranked by their relative response to fluconazole by using both improvement in survival and reduction in fungal burden in the kidney. The resulting rank order of in vivo response did not match the MICs obtained by using the M27-A criterion, and these MICs significantly overestimated the resistance of three of the six isolates tested. However, if the MIC was determined after 24 h of incubation and the endpoint required a less restrictive 50% reduction in growth, MICs which better matched the in vivo response pattern could ...Continue Reading

References

Dec 11, 1992·Journal of Clinical Microbiology·A Espinel-IngroffM G Rinaldi
Jan 1, 1987·Reviews of Infectious Diseases·M Borgers, M A Van de Ven
Apr 1, 1995·Antimicrobial Agents and Chemotherapy·J H RexE J Anaissie
Oct 1, 1994·Diagnostic Microbiology and Infectious Disease·A Espinel-IngroffJ N Galgiani
Aug 1, 1994·The Journal of Infectious Diseases·E J AnaissieV Paetznick
Jan 1, 1994·Antimicrobial Agents and Chemotherapy·J L Rodriguez-Tudela, J V Martinez-Suarez
Oct 1, 1993·Clinical Microbiology Reviews·J H RexJ N Galgiani
Jan 1, 1993·Antimicrobial Agents and Chemotherapy·R A FromtlingG D Roberts
Mar 1, 1996·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·A Espinel-IngroffD Reich
Dec 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M A PfallerJ H Rex
Sep 1, 1996·Journal of Clinical Microbiology·A L Barry, S D Brown
May 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M A PfallerM G Rinaldi

❮ Previous
Next ❯

Citations

Sep 19, 2000·Antimicrobial Agents and Chemotherapy·K W HenryT D Edlind
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·K A MarrT C White
Mar 10, 2001·Journal of Chemotherapy·R FringuelliA Vecchiarelli
Aug 15, 2001·Pharmacotherapy·H L Hoffman, M A Pfaller
Oct 6, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A VillanuevaC A Sable
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Sevtap ArikanJohn H Rex
Oct 9, 2002·Molecular Microbiology·Thomas EdlindJoseph Nickels
Sep 22, 2007·Medical Mycology·Sevtap Arikan
Jul 23, 2009·Expert Review of Anti-infective Therapy·Emilia CantónJavier Pemán
Apr 23, 2014·Mycopathologia·Mahzad EramiLeila Hosseinpour
Sep 21, 2016·Antimicrobial Agents and Chemotherapy·Arturo Luna-TapiaGlen E Palmer
Feb 13, 2020·Nature Reviews. Microbiology·Judith Berman, Damian J Krysan
Oct 5, 2001·Clinical Microbiology Reviews·J H RexD W Warnock
Jan 27, 2006·Antimicrobial Agents and Chemotherapy·Taiga MiyazakiShigeru Kohno
May 6, 2011·Canadian Journal of Microbiology·Silvia BoreckáHelena Bujdáková
Jul 23, 2014·Antimicrobial Agents and Chemotherapy·George PankeyAbdulrahim Ismail
Apr 30, 2016·Jundishapur Journal of Microbiology·Kamiar ZomorodianAli Poostforoush Fard
Feb 11, 2015·Antimicrobial Agents and Chemotherapy·Arturo Luna-TapiaGlen E Palmer
Oct 17, 2018·Antimicrobial Agents and Chemotherapy·Arturo Luna-TapiaGlen E Palmer
Oct 12, 2019·The Journal of Antimicrobial Chemotherapy·Andrew T NishimotoP David Rogers
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·Mette D JacobsenFrank C Odds
May 19, 2000·Antimicrobial Agents and Chemotherapy·F BarchiesiG Scalise
May 11, 2016·Medical Mycology·Laura Judith Marcos-ZambranoJesús Guinea

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.